CytoSorbents Corp (NASDAQ:CTSO) shares are trading higher by 21% to $0.85 during Tuesday’s session after the company entered into a new $20 million credit facility with Avenue Capital Group. The ...

Q4 Financials: Record Product Revenue, Record-Implying Guidance, Several Catalysts To Ramp 2014… CytoSorbents (CTSO) reported results for the fourth quarter ending December 31, 2013 and as expected ...

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter ...

Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, ...

Oversubscribed Rights Offering Generated $6.25 Million in Aggregate Gross Proceeds Offering Proceeds Satisfies Debt Covenant, Unlocking $5.0 Million in Restricted Cash Currently on the Balance Sheet ...

CytoSorbents (OTC BB:CTSO) continues to make meaningful progress with its measured roll-out of CytoSorb in Europe which includes making key additions to its sales and marketing team. CTSO's CEO, Phil ...

(RTTNews) - CytoSorbents Corp. (CTSO), which provides the treatment of life-threatening conditions in intensive care and cardiac surgery using CytoSorb blood purification, made additional comments on ...

Cytosorbents Corp. Annual stock financials by MarketWatch. View the latest CTSO financial statements, income statements and financial ratios.

Health Care Equipment Supplier CytoSorbents Shares Dip Despite Projected Revenue Growth CytoSorbents is progressing with U.S. FDA and Health Canada reviews for its DrugSorb-ATR device. CytoSorbents ...

PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit ...